Tuba Hacibekiroğlu1, Yasin Kalpakçı1, Ahmed Cihad Genç2, İlhan Hacibekiroğlu3, Cenk Sunu1, Adem Saricaoğlu4, Yakup Tomak5, Oğuz Karabay6, Mehmet Köroğlu1. 1. Department of Hematology, Faculty of Medicine, Sakarya University, Sakarya, Turkey 2. Department of Internal Medicine, Sakarya University, Research and Training Hospital, Sakarya, Turkey 3. Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, Turkey 4. Department of Blood Transfusion Center, Faculty of Medicine, Sakarya University, Sakarya, Turkey 5. Department of Anesthesiology and Pain Medicine, Faculty of Medicine, Sakarya University Sakarya, Turkey 6. Department of Infectious Disease, Faculty of Medicine, Sakarya University, Sakarya, Turkey
Abstract
Background/aim: In this study, we aim to investigate the efficacy of convalescent plasma (CP) according to blood groups (BGs) in the treatment of critically ill patients diagnosed with COVID-19. Materials and methods: Twenty-eight critically ill and laboratory-confirmed COVID-19 patients who were admitted to the intensive care unit (ICU) of Sakarya University, Medical Faculty were included in the study. Patients were divided into 2 groups: patients who received anti-A antibody (Ab) containing CP (BG O and B) and those who did not receive CP containing anti-A Ab (BG A and AB). Results: Among the 28 patients, 13 patients received anti-A Ab containing CP (BG; B: 6, O: 7) and 15 patients did not receive anti-A Ab CP (BG; A: 13, AB: 2). Duration in ICU, the rates of mechanical ventilation (MV) support and vasopressor support, the case fatality rate, and the discharge rate were lower in patients who received CP containing anti-A Ab than not containing anti-A Ab CP. However, only the difference in the rate of MV support achieved statistically significance (P = 0.04) Conclusion: In our study, it was observed that the efficiency of CP without anti-A antibody was lower than that of plasma containing anti-A antibody, although it was not statistically significant. This result is thought to be due to the anti-A antibody’s ability to block the ACE2 receptor. We believe that this hypothesis should be investigated in controlled studies with higher patient numbers. This work is licensed under a Creative Commons Attribution 4.0 International License.
Background/aim: In this study, we aim to investigate the efficacy of convalescent plasma (CP) according to blood groups (BGs) in the treatment of critically illpatients diagnosed with COVID-19. Materials and methods: Twenty-eight critically ill and laboratory-confirmed COVID-19patients who were admitted to the intensive care unit (ICU) of Sakarya University, Medical Faculty were included in the study. Patients were divided into 2 groups: patients who received anti-A antibody (Ab) containing CP (BG O and B) and those who did not receive CP containing anti-A Ab (BG A and AB). Results: Among the 28 patients, 13 patients received anti-A Ab containing CP (BG; B: 6, O: 7) and 15 patients did not receive anti-A Ab CP (BG; A: 13, AB: 2). Duration in ICU, the rates of mechanical ventilation (MV) support and vasopressor support, the case fatality rate, and the discharge rate were lower in patients who received CP containing anti-A Ab than not containing anti-A Ab CP. However, only the difference in the rate of MV support achieved statistically significance (P = 0.04) Conclusion: In our study, it was observed that the efficiency of CP without anti-A antibody was lower than that of plasma containing anti-A antibody, although it was not statistically significant. This result is thought to be due to the anti-A antibody’s ability to block the ACE2 receptor. We believe that this hypothesis should be investigated in controlled studies with higher patient numbers. This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors: Yunfeng Cheng; Yufeng Cheng; Gregory Cheng; C H Chui; F Y Lau; Paul K S Chan; Margaret H L Ng; Joseph J Y Sung; Raymond S M Wong Journal: JAMA Date: 2005-03-23 Impact factor: 56.272